<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">rsp</journal-id><journal-title-group><journal-title xml:lang="ru">Научно-практическая ревматология</journal-title><trans-title-group xml:lang="en"><trans-title>Rheumatology Science and Practice</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1995-4484</issn><issn pub-type="epub">1995-4492</issn><publisher><publisher-name>IMA-PRESS, LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.47360/1995-4484-2024-203-215</article-id><article-id custom-type="elpub" pub-id-type="custom">rsp-3551</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL RESEARCH</subject></subj-group></article-categories><title-group><article-title>Индексы активности поражения и повреждения кожи у пациентов с системной красной волчанкой — CLASI и R-CLASI</article-title><trans-title-group xml:lang="en"><trans-title>Indexes of skin activity and damage in patients with systemic lupus erythematosus – CLASI and R-CLASI</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1318-1894</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шумилова</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Shumilova</surname><given-names>А. А.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Шумилова Анастасия Александровна</p><p>115522, Москва, Каширское шоссе, 34а</p></bio><bio xml:lang="en"><p>Anastasiia A. Shumilova</p><p>115522, Moscow, Kashirskoye Highway, 34A</p></bio><email xlink:type="simple">dr.anashumilova@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5217-4932</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Чельдиева</surname><given-names>Ф. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Cheldieva</surname><given-names>F. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>115522, Москва, Каширское шоссе, 34а</p></bio><bio xml:lang="en"><p>Fariza A. Cheldieva</p><p>115522, Moscow, Kashirskoye Highway, 34A</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6685-7670</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Нурбаева</surname><given-names>К. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Nurbaeva</surname><given-names>К. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>115522, Москва, Каширское шоссе, 34а;</p><p>125993, Москва, ул. Баррикадная, 2/1, стр. 1</p></bio><bio xml:lang="en"><p>Kamila S. Nurbaeva</p><p>115522, Moscow, Kashirskoye Highway, 34A;</p><p>125993, Moscow, Barrikadnaya str., 2/1, building 1 </p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6399-8766</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Травкина</surname><given-names>Е. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Travkiva</surname><given-names>Е. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>115522, Москва, Каширское шоссе, 34а</p></bio><bio xml:lang="en"><p>Ekaterina I. Travkiva</p><p>115522, Moscow, Kashirskoye Highway, 34A</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3552-2522</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Решетняк</surname><given-names>Т. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Reshetnyak</surname><given-names>Т. М.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Решетняк Татьяна Магомедалиевна</p><p>115522, Москва, Каширское шоссе, 34а;</p><p>125993, Москва, ул. Баррикадная, 2/1, стр. 1</p></bio><bio xml:lang="en"><p>Tatiana M. Reshetnyak</p><p>115522, Moscow, Kashirskoye Highway, 34A;</p><p>125993,  Moscow, Barrikadnaya str., 2/1, building 1</p></bio><email xlink:type="simple">t_reshetnyak@yahoo.com</email><xref ref-type="aff" rid="aff-3"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">ФГБНУ «Научно-исследовательский институт ревматологии&#13;
им. В.А. Насоновой»<country>Россия</country></aff><aff xml:lang="en">V.A. Nasonova Research Institute of Rheumatology<country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru">ФГБНУ «Научно-исследовательский институт ревматологии&#13;
им. В.А. Насоновой»;&#13;
ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России<country>Россия</country></aff><aff xml:lang="en">V.A. Nasonova Research Institute of Rheumatology;&#13;
Russian Medical Academy of Continuous Professional Education&#13;
of the Ministry of Healthcare of the Russian Federation<country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru">ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»;&#13;
ФГБОУ ДПО «Российская медицинская академия  непрерывного профессионального образования» Минздрава России<country>Россия</country></aff><aff xml:lang="en">V.A. Nasonova Research Institute of Rheumatology; &#13;
Russian Medical Academy of Continuous Professional Education&#13;
of the Ministry of Healthcare of the Russian Federation<country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>29</day><month>04</month><year>2024</year></pub-date><volume>62</volume><issue>2</issue><fpage>203</fpage><lpage>215</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Шумилова А.А., Чельдиева Ф.А., Нурбаева К.С., Травкина Е.И., Решетняк Т.М., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Шумилова А.А., Чельдиева Ф.А., Нурбаева К.С., Травкина Е.И., Решетняк Т.М.</copyright-holder><copyright-holder xml:lang="en">Shumilova А.А., Cheldieva F.A., Nurbaeva К.S., Travkiva Е.I., Reshetnyak Т.М.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://rsp.mediar-press.net/rsp/article/view/3551">https://rsp.mediar-press.net/rsp/article/view/3551</self-uri><abstract><sec><title>Введение</title><p>Введение. Разработка индексов активности поражения и повреждения кожи при системной красной волчанке (СКВ) связана с необходимостью количественной оценки ее изменений. Индекс площади и тяжести кожной волчанки (CLASI, Cutaneous Lupus Disease Area and Severity Index) и его модифицированная версия (R-CLASI, the Revised Cutaneous Lupus Erythematosus Disease Area and Severity Index) – это инструменты для количественной оценки изменений кожи и слизистых у пациентов как с кожной красной волчанкой (ККВ), так и с ее системным вариантом.</p><p>Цель исследования – валидировать индексы CLASI и R-CLASI в российской когорте пациентов с системной красной волчанкой и сопоставить результат их использования с дерматологическими оценками качества жизни.</p></sec><sec><title>Материал и методы</title><p>Материал и методы. В исследование включено 55 больных СКВ с различными видами поражения кожи и слизистых; медиана возраста – 30,0 [26,0; 40,0] лет, медиана длительности заболевания – 7,0 [3,0; 14,0] лет. Для оценки активного (обратимого) поражения и необратимого повреждения кожи использовались индексы CLASI и R-CLASI; для общей оценки активности и повреждения при СКВ – соответственно индекс активности системной красной волчанки 2000 (SLEDAI-2K, Systemic Lupus Erythematosus Disease Activity Index 2000) и индекс повреждения (ИП) SLICС/ACR (SLICC/ACR DI, Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index).</p></sec><sec><title>Результаты</title><p>Результаты. Наиболее частым вариантом поражения кожи у пациентов с СКВ была острая кожная красная волчанка (ОККВ), наблюдавшаяся в 45% случаев, а также алопеция, выявленная в 62% случаев. Медиана индекса активности (ИА) CLASI составила 5,0 [2,0; 11,0], медиана ИА R-CLASI – 7,0 [3,0; 18,0] баллов; медиана ИП CLASI – 5,0 [2,0; 11,0], медиана ИП R-CLASI – 2,0 [0,0; 7,0] балла. Выявлена статистически значимая взаимосвязь CLASI и R-CLASI со степенью активности в кожно-слизистом домене по SLEDAI-2K и ИП при СКВ. По данным ROC-анализа, индексы CLASI и R-CLASI показали высокую чувствительность (ИА CLASI – 98%, R-CLASI – 93%, ИП CLASI и R-CLASI – 91%) и специфичность (ИА CLASI – 64%, R-CLASI – 71%, ИП CLASI и R-CLASI – 86%).</p></sec><sec><title>Заключение</title><p>Заключение. Индексы CLASI и R-CLASI отражают уровень активности и тяжести поражения кожи, при этом их более высокие значения приходятся на более выраженное поражение кожи и значительное влияние на общее самочувствие больных СКВ. Пациенты с высокими значениями этих индексов часто испытывают ощущение смущения, неловкости, сложности при выполнении повседневных задач и ограничения в социальной жизни. Для оценки выраженности поражения кожи и слизистых у пациентов с СКВ на территории Российской Федерации целесообразно использование индексов CLASI и R-CLASI.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Introduction</title><p>Introduction. Cutaneous Lupus Disease Area and Severity Index (CLASI) and its modified version, the Revised Cutaneous Lupus Erythematosus Disease Areas and Severity Index (R-CLASI) are tools for quantifying skin and mucosal lesions in patients with both cutaneous lupus erythematosus and its systemic variant. Evaluation of the scales of activity and skin damage in systemic lupus erythematosus (SLE) is associated with the need to stratify their quantitative characteristics. The Cutaneous Lupus Disease Area and Severity Index (CLASI) and its modified version the Revised Cutaneous Lupus Erythematosus Disease Area and Severity Index (R-CLASI) are a tool for quantifying skin and mucosal lesions in patients with both cutaneous lupus erythematosus (CLE) and its system version.</p></sec><sec><title>Objective</title><p>Objective. To validate the indexes of objective assessment of skin activity and damage CLASI and R-CLASI in the Russian cohort of patients with systemic lupus erythematosus and compare it with dermatological assessments of the quality of life.</p></sec><sec><title>Material and methods</title><p>Material and methods. The study included 55 patients with SLE with various types of skin and mucosal lesions, the median age was 30.0 [26.0; 40.0] years, the duration of the disease was 7.0 [3.0; 14.0] years. To assess the active (reversible) lesion and irreversible skin damage, the CLASI and R-CLASI indexes were used, for the general assessment of activity and damage in SLE, the SLEDAI-2K and SLICC/ACR DI were used.</p></sec><sec><title>Results</title><p>Results. The most common variant of skin lesions in patients with SLE is acute cutaneous lupus erythematosus (ACLE) – 45%, as well as alopecia, which occurs in 62% of cases. The median activity index for CLASI was 5.0 [2.0; 11.0], and R-CLASI was 7.0 [3.0; 18.0]; the median damage index for CLASI was 5.0 [2.0; 11.0], and R-CLASI was 2.0 [0.0; 7.0]. A significant relationship was revealed between the medians of CLASI and R-CLASI scores depending on the degree of activity according to SLEDAI-2K (Systemic Lupus Erythematosus Disease Activity Index) and the damage Index (DI) in SLE (SLICC/ACR DI, Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index) when recalculating these indexes only for skin and mucous lesions. According to the ROC analysis, the CLASI and R-CLASI skin activity and damage indices showed high sensitivity (CLASI activity index – 98%, R-CLASI – 93%, CLASI and R-CLASI damage index – 91%) and specificity (CLASI activity index – 64%, R-CLASI – 71%, CLASI and R-CLASI damage index – 86%).</p></sec><sec><title>Conclusion</title><p>Conclusion. To assess the severity of skin and mucosal lesions in patients with SLE in the Russian Federation, it is reasonable to use the CLASI and R-CLASI indices. The CLASI and R-CLASI indices reflect the level of activity and severity of skin lesions, with higher values of these indices indicating more severe skin lesions and a significant impact on the overall well-being of SLE patients. Patients with high values of these indices often experience feelings of embarrassment, discomfort, difficulty in performing daily tasks, and limitations in social life. To assess the severity of skin and mucous lesions in patients with SLE in the Russian Federation, it is advisable to use the CLASI and R-CLASI indexes.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>системная красная волчанка</kwd><kwd>активность заболевания</kwd><kwd>поражение кожи</kwd><kwd>алопеция</kwd><kwd>поражение слизистых</kwd></kwd-group><kwd-group xml:lang="en"><kwd>systemic lupus erythematosus</kwd><kwd>disease activity</kwd><kwd>skin lesion</kwd><kwd>alopecia</kwd><kwd>mucosal lesion</kwd></kwd-group><funding-group xml:lang="ru"><funding-statement>Исследование проводилось в рамках темы ФГБНУ НИИР им. В.А. Насоновой FURS-2022-003. Исследование одномоментное, одобрено комитетом по этике при ФГБНУ НИИР им. В.А. Насоновой (протокол № 25 от 15.12.2022).</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Насонов ЕЛ (ред.). Ревматология. Российские клинические рекомендации. М.:ГЭОТАР-Медиа;2017.</mixed-citation><mixed-citation xml:lang="en">Nasonov EL (ed.). Rheumatology. Russian clinical recommendations. Moscow:GEOTAR-Media; 2017 (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Бадокин ВВ (ред.). Ревматология. Клинические лекции. М.:Литтера;2012.</mixed-citation><mixed-citation xml:lang="en">Badokin VV (ed.). Rheumatology. Clinical lectures. Moscow:Littera;2012 (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Kuhn A, Wenzel J, Bijl M. Lupus erythematosus revisited. Semin Immunopathol. 2016;38(1):97-112. doi: 10.1007/s00281-015-0550-0</mixed-citation><mixed-citation xml:lang="en">Kuhn A, Wenzel J, Bijl M. Lupus erythematosus revisited. Semin Immunopathol. 2016;38(1):97-112. doi: 10.1007/s00281-015-0550-0</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Deng GM, Tsokos GC. Pathogenesis and targeted treatment of skin injury in SLE. Nat Rev Rheumatol. 2015;11(11):663-669. doi: 10.1038/nrrheum.2015.106</mixed-citation><mixed-citation xml:lang="en">Deng GM, Tsokos GC. Pathogenesis and targeted treatment of skin injury in SLE. Nat Rev Rheumatol. 2015;11(11):663-669. doi: 10.1038/nrrheum.2015.106</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Насонов ЕЛ, Авдеева АС. Иммуновоспалительные ревматические заболевания, связанные с интерфероном типа I: новые данные. Научно-практическая ревматология. 2019;57(4):452- 461. doi: 10.14412/1995-4484-2019- 452-461</mixed-citation><mixed-citation xml:lang="en">Nasonov EL, Avdeeva AS. Immunoinflammatory rheumatic diseases associated with type I interferon: New evidence. NauchnoPrakticheskaya Revmatologia = Rheumatology Science and Practice. 2019;57(4):452-461. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Gilliam JN, Sontheimer RD. Distinctive cutaneous subsets in the spectrum of lupus erythematosus. J Am Acad Dermatol. 1981;4:471-475. doi: 10.1016/s0190-9622(81)80261-7</mixed-citation><mixed-citation xml:lang="en">Gilliam JN, Sontheimer RD. Distinctive cutaneous subsets in the spectrum of lupus erythematosus. J Am Acad Dermatol. 1981;4:471-475. doi: 10.1016/s0190-9622(81)80261-7</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Шумилова АА, Травкина ЕИ, Решетняк ТМ. Поражение кожи при системной красной волчанке. Часть 1: классификация, этиология, патогенез. Современная ревматология. 2022;16(3):7- 13. doi: 10.14412/1996-7012-2022-3-7-13</mixed-citation><mixed-citation xml:lang="en">Shumilova AA, Travkina EI, Reshetnyak TM. Skin lesions in systemic lupus erythematosus. Part 1: Classification, etiology, pathogenesis. Modern Rheumatology Journal. 2022;16(3):7-13 (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Ahmad Fadzil MH, Ihtatho D, Mohd Affandi A, Hussein SH. Objective assessment of psoriasis erythema for PASI scoring. J Med Eng Technol. 2009;33(7):516-524. doi: 10.1080/07434610902744074</mixed-citation><mixed-citation xml:lang="en">Ahmad Fadzil MH, Ihtatho D, Mohd Affandi A, Hussein SH. Objective assessment of psoriasis erythema for PASI scoring. J Med Eng Technol. 2009;33(7):516-524. doi: 10.1080/07434610902744074</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Leshem YA, Hajar T, Hanifin JM, Simpson EL. What the Eczema Area and Severity Index score tells us about the severity of atopic dermatitis: An interpretability study. Br J Dermatol. 2015;172(5):1353-1357. doi: 10.1111/bjd.13662.</mixed-citation><mixed-citation xml:lang="en">Leshem YA, Hajar T, Hanifin JM, Simpson EL. What the Eczema Area and Severity Index score tells us about the severity of atopic dermatitis: An interpretability study. Br J Dermatol. 2015;172(5):1353-1357. doi: 10.1111/bjd.13662.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Faust HB, Gonin R, Chuang TY, Lewis CW, Melfi CA, Farmer ER. Reliability testing of the dermatology index of disease severity (DIDS). An index for staging the severity of cutaneous inflammatory disease. Arch Dermatol. 1997;133(11):1443-1448.</mixed-citation><mixed-citation xml:lang="en">Faust HB, Gonin R, Chuang TY, Lewis CW, Melfi CA, Farmer ER. Reliability testing of the dermatology index of disease severity (DIDS). An index for staging the severity of cutaneous inflammatory disease. Arch Dermatol. 1997;133(11):1443-1448.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Albrecht J, Werth VP. Development of the CLASI as an outcome instrument for cutaneous lupus erythematosus. Dermatol Ther. 2007;20(2):93-101. doi: 10.1111/j.1529-8019.2007.00117.x</mixed-citation><mixed-citation xml:lang="en">Albrecht J, Werth VP. Development of the CLASI as an outcome instrument for cutaneous lupus erythematosus. Dermatol Ther. 2007;20(2):93-101. doi: 10.1111/j.1529-8019.2007.00117.x</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Krathen MS, Dunham J, Gaines E, Junkins-Hopkins J, Kim E, Kolasinski SL, et al. The Cutaneous Lupus Erythematosus Disease Activity and Severity Index: Expansion for rheumatology and dermatology. Arthritis Rheum. 2008;59(3):338-344. doi: 10.1002/art.23319</mixed-citation><mixed-citation xml:lang="en">Krathen MS, Dunham J, Gaines E, Junkins-Hopkins J, Kim E, Kolasinski SL, et al. The Cutaneous Lupus Erythematosus Disease Activity and Severity Index: Expansion for rheumatology and dermatology. Arthritis Rheum. 2008;59(3):338-344. doi: 10.1002/art.23319</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Albrecht J, Taylor L, Berlin JA, Dulay S, Ang G, Fakharzadeh S, et al. The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): An outcome instrument for cutaneous lupus erythematosus. J Invest Dermatol. 2005;125(5):889-894. doi: 10.1111/j.0022-202X.2005.23889.x</mixed-citation><mixed-citation xml:lang="en">Albrecht J, Taylor L, Berlin JA, Dulay S, Ang G, Fakharzadeh S, et al. The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): An outcome instrument for cutaneous lupus erythematosus. J Invest Dermatol. 2005;125(5):889-894. doi: 10.1111/j.0022-202X.2005.23889.x</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Kuhn A, Meuth AM, Bein D, Amler S, Beissert S, Böhm M, et al. Revised Cutaneous Lupus Erythematosus Disease Area and Severity Index (RCLASI): A modified outcome instrument for cutaneous lupus erythematosus. Br J Dermatol. 2010;163(1):83-92. doi: 10.1111/j.1365-2133.2010.09799.x</mixed-citation><mixed-citation xml:lang="en">Kuhn A, Meuth AM, Bein D, Amler S, Beissert S, Böhm M, et al. Revised Cutaneous Lupus Erythematosus Disease Area and Severity Index (RCLASI): A modified outcome instrument for cutaneous lupus erythematosus. Br J Dermatol. 2010;163(1):83-92. doi: 10.1111/j.1365-2133.2010.09799.x</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Sprow G, Dan J, Merola JF, Werth VP. Emerging therapies in cutaneous lupus erythematosus. Front Med (Lausanne). 2022;9:968323. doi: 10.3389/fmed.2022.968323</mixed-citation><mixed-citation xml:lang="en">Sprow G, Dan J, Merola JF, Werth VP. Emerging therapies in cutaneous lupus erythematosus. Front Med (Lausanne). 2022;9:968323. doi: 10.3389/fmed.2022.968323</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) – A simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210-216. doi: 10.1111/j.1365-2230.1994.tb01167.x</mixed-citation><mixed-citation xml:lang="en">Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) – A simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210-216. doi: 10.1111/j.1365-2230.1994.tb01167.x</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Григорян НС, Мельниченко АБ, Кочергин НГ. Семейный дерматологический индекс качества жизни. Доктор.Ру. 2011;3(62):53-56.</mixed-citation><mixed-citation xml:lang="en">Grigoryan NS, Melnichenko AB, Kochergin NG. Family dermatological index of quality of life. Doctor.Ru. 2011;3(62):53-56 (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Cardiff University Department of Dermatology. URL: www.cardiff.ac.uk/dermatology/quality-of-life/dermatology-qualityof-life-index-dlqi/ (Accessed: 19th February2019).</mixed-citation><mixed-citation xml:lang="en">Cardiff University Department of Dermatology. URL: www.cardiff.ac.uk/dermatology/quality-of-life/dermatology-qualityof-life-index-dlqi/ (Accessed: 19th February2019).</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Cash TF, Fleming EC. The impact of body image experiences: Development of the body image quality of life inventory. Int J Eat Disord. 2002;31(4):455-460. doi: 10.1002/eat.10033</mixed-citation><mixed-citation xml:lang="en">Cash TF, Fleming EC. The impact of body image experiences: Development of the body image quality of life inventory. Int J Eat Disord. 2002;31(4):455-460. doi: 10.1002/eat.10033</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Баранская ЛТ, Ткаченко АЕ, Татаурова СС. Адаптация методики исследования образа тела в клинической психологии. Образование и наука. 2008;(3):63-69.</mixed-citation><mixed-citation xml:lang="en">Baranskaya LT, Tkachenko AE, Tataurova SS. Adaptation of the methodology of body image research in clinical psychology. The Education and Science Journal. 2008;(3):63-69 (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Petri M, Orbai AM, Alarcón GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677-2686. doi: 10.1002/art.34473</mixed-citation><mixed-citation xml:lang="en">Petri M, Orbai AM, Alarcón GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677-2686. doi: 10.1002/art.34473</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Gladman DD, Ibañez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002;29(2):288-291.</mixed-citation><mixed-citation xml:lang="en">Gladman DD, Ibañez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002;29(2):288-291.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum. 1996;39(3):363-369. doi: 10.1002/art.1780390303</mixed-citation><mixed-citation xml:lang="en">Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum. 1996;39(3):363-369. doi: 10.1002/art.1780390303</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Klein R, Moghadam-Kia S, LoMonico J, Okawa J, Coley C, Taylor L, et al. Development of the CLASI as a tool to measure disease severity and responsiveness to therapy in cutaneous lupus erythematosus. Arch Dermatol. 2011;147(2):203-208. doi: 10.1001/archdermatol.2010.435</mixed-citation><mixed-citation xml:lang="en">Klein R, Moghadam-Kia S, LoMonico J, Okawa J, Coley C, Taylor L, et al. Development of the CLASI as a tool to measure disease severity and responsiveness to therapy in cutaneous lupus erythematosus. Arch Dermatol. 2011;147(2):203-208. doi: 10.1001/archdermatol.2010.435</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Chakka S, Krain RL, Concha JSS, Chong BF, Merola JF, Werth VP. The CLASI, a validated tool for the evaluation of skin disease in lupus erythematosus: A narrative review. Ann Transl Med. 2021;9(5):431. doi: 10.21037/atm-20-5048</mixed-citation><mixed-citation xml:lang="en">Chakka S, Krain RL, Concha JSS, Chong BF, Merola JF, Werth VP. The CLASI, a validated tool for the evaluation of skin disease in lupus erythematosus: A narrative review. Ann Transl Med. 2021;9(5):431. doi: 10.21037/atm-20-5048</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">AlE’ed A, Aydin POA, Al Mutairi N, AlSaleem A, Sonmez HE, Henrickson M, et al. Validation of the Cutaneous Lupus Erythematosus Disease Area and Severity Index and pSkindex27 for use in childhood-onset systemic lupus erythematosus. Lupus Sci Med. 2018;5(1):e000275. doi: 10.1136/lupus-2018-000275</mixed-citation><mixed-citation xml:lang="en">AlE’ed A, Aydin POA, Al Mutairi N, AlSaleem A, Sonmez HE, Henrickson M, et al. Validation of the Cutaneous Lupus Erythematosus Disease Area and Severity Index and pSkindex27 for use in childhood-onset systemic lupus erythematosus. Lupus Sci Med. 2018;5(1):e000275. doi: 10.1136/lupus-2018-000275</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Klein R, Moghadam-Kia S, Taylor L, Coley C, Okawa J, LoMonico J, et al. Quality of life in cutaneous lupus erythematosus. J Am Acad Dermatol. 2011;64(5):849-858. doi: 10.1016/j.jaad.2010.02.008</mixed-citation><mixed-citation xml:lang="en">Klein R, Moghadam-Kia S, Taylor L, Coley C, Okawa J, LoMonico J, et al. Quality of life in cutaneous lupus erythematosus. J Am Acad Dermatol. 2011;64(5):849-858. doi: 10.1016/j.jaad.2010.02.008</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
